FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.
Shenzhen Hepalink Pharmaceutical said it has reached an agreement to develop and commercialize in Greater China a cardiovascular candidate from Resverlogix Corp. in a deal that could even include wider territorial sales if successful.
The FDA halted the manufacture of Medtronic's SynchroMed II Implantable Infusion Pump Systems, citing repeatedly failing to correct violations of the agency's quality system regulations in a consent decree filed against company CEO Omar Ishrak and Senior Vice President Thomas Tefft.
Wednesday's a big day for Amgen, whose dual-acting cancer vaccine/viral therapy is coming up for review by an FDA panel of experts.
An internal FDA review of Amgen's study of its cancer-killing virus talimogene laherparepvec (T-Vec), released Monday morning, raises red flags for this drug, presenting some thorny questions for the company's regulatory team to answer.
A special panel at Japan's Ministry of Health, Labour and Welfare designated 11 unapproved and off-label drugs as applicable to unmet medical needs, putting them in line for fast-track review in Japan by the Pharmaceuticals and Medical Devices Agency.
Cipla-backed Stempeutics, an Indian advanced clinical stage biotech company based in Bangalore, said it is the first company in the world to be granted a process patent by the State Intellectual Property Office of China for a stem cell drug treatment based on pooling technology that could potentially be used in the treatment of critical limb ischemia.
Sumitomo Dainippon Pharma said the results of Phase III clinical trials for its Latuda schizophrenia treatment in Japan disappointed and it would evaluate the next steps forward, but noted that a separate clinical trial on a bipolar disorder candidate would proceed.
China got international plaudits on the recent World Malaria Day not so much for handling its own cases of the disease but for providing the world with what one expert called "the best" treatment, artemisinin-based combination therapies.
China's FDA is laying plans to work directly with its U.S. counterpart to learn the secrets of drug and medical-device regulation and bring China drug-making and other regulated industries up to international standards.